← All sarcoma trials
Recruiting now—All ages

Localized Leiomyosarcoma Biomarker Protocol

Sponsor: University of Michigan Rogel Cancer Center · NCT04925089 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Leiomyosarcoma

What it tests

  • Blood and Tissue collectionother

Where it's running3 sites

  • University of Michigan

    Ann Arbor, Michigan 48109

    Recruiting now

  • Mayo Clinic

    Rochester, Minnesota 55901

    Recruiting now
    • Brittany Siontis, MD(contact)

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37232

    Recruiting now
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Patients with localized leiomyosarcoma (LMS) of extremity, body wall or retroperitoneum
* Grade 2 or 3, or high-grade LMS
* Tumor size \>5 cm in greatest dimension
* Primary tumor amenable to complete resection
* There is no age requirement
* Participant agrees to receive neoadjuvant doxorubicin and ifosfamide combination chemotherapy
* If pre-operative radiation is administered, it must be administered after chemotherapy. Post-operative radiation may be administered
* Archival tumor tissue (either frozen sample, tissue block containing tumor, or minimum of 4 unstained slides and 1 H\&E stained slide) from diagnostic or pre-treatment biopsy available for study research

Updated 2026-02-17 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.